Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Vangeel, Laura; Chiu, Winston; Jonghe, Steven De; Maes, Piet; Slechten, Bram; Raymenants, Joren; André, Emmanuel; Leyssen, Pieter; Neyts, Johan; Jochmans, Dirk

doi:10.1016/j.antiviral.2022.105252

articleAntiviral ResearchJan 24, 2022HYBRID OA

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

LVLaura Vangeel WCWinston Chiu SDSteven De Jonghe PMPiet Maes BSBram Slechten

Rega Institute for Medical Research · KU Leuven

PubMed

Indexed incrossrefpubmed

Abstract

We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524, molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor nirmatrelvir against the ancestral SARS-CoV2 strain and the five variants of concern including Omicron. VeroE6-GFP cells were pre-treated overnight with serial dilutions of the compounds before infection. The GFP signal was determined by high-content imaging on day 4 post-infection. All molecules have equipotent antiviral activity against the ancestral virus and the VOCs Alpha, Beta, Gamma, Delta and Omicron. These findings are in line with the observation that the target proteins of these antivirals (respectively the viral RNA…

Citation impact

430

total citations

FWCI: 42.34
Percentile: 100%
References: 28

Citations per year

Authors

10

Topics & keywords

Topics

Keywords

Virology
Protease
Virus
RNA
Nucleoside
In vitro
Biology
Serial dilution

No related works found for this paper.